The immunologic basis for the treatment of psoriasis with new biologic agents.
about
Anti-TNF agents for paediatric psoriasisAnti-TNF agents for paediatric psoriasisPromising new treatments for psoriasisPsoriasis pathophysiology: current concepts of pathogenesisIncreased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgarisDermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].Biologics in dermatology: an integrated reviewLow expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis.Emerging drugs for moderate-to-severe psoriasis.Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis.Identification and characterization of a human monoclonal antagonistic antibody AL-57 that preferentially binds the high-affinity form of lymphocyte function-associated antigen-1.Type I interferon: potential therapeutic target for psoriasis?Tolerability, pharmacokinetics and pharmacodynamics of CMAB001, an anti-CD11a antibody, in Chinese healthy volunteers and psoriatic patients.Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumabBiologics in dermatologic therapy - an update.Serum leptin and adiponectin levels in Korean patients with psoriasis.The immunologic effects of estrogen on psoriasis: A comprehensive review.Treating psoriatic arthritis: how effective are TNF antagonists?Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgarisMicrobes, the gut and ankylosing spondylitis.Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study.Development of autoimmune hepatitis in a psoriasis patient without immunosuppressive therapy.Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease.Immunologic biomarkers for clinical and therapeutic management of psoriasis.Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier.Pathogenic mechanisms shared between psoriasis and cardiovascular diseaseProgress in understanding the immunopathogenesis of psoriasisIncrease in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.Transcriptome classification reveals molecular subtypes in psoriasisCannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition.XP-828l in the treatment of mild to moderate psoriasis: randomized, double-blind, placebo-controlled study.Therapeutic effect of hyperbaric oxygen in psoriasis vulgaris: two case reports and a review of the literature.Biologics in the management of psoriasis.Etanercept in the treatment of plaque psoriasisBiological response modifiers and their potential use in the treatment of inflammatory skin diseases.Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.Genetic basis of psoriasis vulgaris and its pharmacogenetic potential.Novel biological immunotherapies for psoriasis.
P2860
Q24187673-A17E8CB0-D5C7-4E83-B2B3-E2B65D7F0B56Q24201907-F3CAF566-E216-45E4-B715-63598F616C07Q24598008-C96ECE70-A56F-437A-8FE0-4EC5E5D8C80DQ24674984-5AAE290B-250F-45DE-B800-23FA95B593D6Q24676186-D1C233F3-99DA-4D52-A5B2-53FEA704CA03Q24816844-9E4EF50A-4A35-487F-B424-098AF35915AAQ25256974-98C92B76-08E1-4EFF-AAB1-3AECB5A6623AQ27004638-C52FA76A-2CFC-4F64-A8AC-2C7669CD0E0EQ30525640-48B05411-2208-45AB-A999-5FF7370E4D72Q30984470-B5BF7427-5D5B-44B8-B833-6A93C5653559Q33216851-90BBE0DD-68D8-4FED-8223-8749F94EA40BQ33252795-46D7A6FF-6FCC-49A8-A096-9FCD1C861AA6Q33354097-78053272-0CE0-4F6E-B2C8-7737FA09F004Q33571293-698D8C5D-5207-441A-BC56-940BEEB7DAC1Q33573621-511D3BBD-EC2C-43E4-B069-29D912D72F1DQ33607620-40DB6F76-79EC-486D-BA70-9C8D443F9C35Q33627496-6CFEBCF6-2895-40B5-B5A2-36F6C541052AQ33640627-83B84FDA-2540-447D-9D11-8D7951857130Q33708854-934D65BE-1561-4996-82B4-CC5F75737E4EQ33757065-451D1535-CA76-4EC2-91D2-33EDAF363206Q33765449-EFAEB4CD-6439-4D1C-B3D0-2C77DE70D38BQ33794253-FAD56F84-A462-4B3C-B10B-5AE62766B8BBQ33873000-4999553B-F238-46CC-9E82-2386FED8DC88Q33915587-4C66E910-345C-4C59-A9AB-3667CAF4DD00Q34030644-3CAE14B6-BBDA-498F-B5E7-1B35DA3353EDQ34085827-9088CEDA-CBBE-4B32-A3B4-D1D297B07482Q34107573-1F859520-B492-4C7C-A10B-3E40CB09D42EQ34215381-22AD096D-1989-48CB-98D8-FC220A82D000Q34245272-98165692-4406-4927-A643-FF79B62B73F0Q34327203-DDE52074-773D-471D-A67E-6BF9F6E74826Q34413204-E678D9ED-783E-48AC-872F-A8674386B3EEQ34414281-5568E305-9A6A-4EEA-B978-3A9413281E9EQ34603524-A60AD0AD-1D11-4102-A67B-5F511E473EECQ34612803-BD6A6C67-4BA4-479C-97BA-18F9CA30F3FEQ34620257-2318B89D-FBFF-4F95-BB76-C2492E1EEE47Q34620263-247803C4-CC32-43E5-9863-40FA5A76ABA6Q35083650-01FCC885-7238-4D98-A048-A87B9DF4525EQ35093640-EE306BE2-0B4D-469A-8413-56D3B539AA7AQ35116099-DB3EA22B-BC7A-4E76-ADE9-FCA643EAE95CQ35164740-06BBA636-084B-4045-8F48-B7F6052A8113
P2860
The immunologic basis for the treatment of psoriasis with new biologic agents.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The immunologic basis for the treatment of psoriasis with new biologic agents.
@ast
The immunologic basis for the treatment of psoriasis with new biologic agents.
@en
The immunologic basis for the treatment of psoriasis with new biologic agents.
@nl
type
label
The immunologic basis for the treatment of psoriasis with new biologic agents.
@ast
The immunologic basis for the treatment of psoriasis with new biologic agents.
@en
The immunologic basis for the treatment of psoriasis with new biologic agents.
@nl
prefLabel
The immunologic basis for the treatment of psoriasis with new biologic agents.
@ast
The immunologic basis for the treatment of psoriasis with new biologic agents.
@en
The immunologic basis for the treatment of psoriasis with new biologic agents.
@nl
P356
P1476
The immunologic basis for the treatment of psoriasis with new biologic agents.
@en
P2093
James G Krueger
P304
1-23; quiz 23-6
P356
10.1067/MJD.2002.120568
P407
P577
2002-01-01T00:00:00Z